108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
针对慢性阻塞性肺疾病中的多条病理生理轴：纳米材料的进展
Authors Zhang Q , Xu S, Yang C, Wang X, Liu T, Zhang X , Qu C, Wu J, Yang J, Xing X
Received 25 May 2025
Accepted for publication 8 September 2025
Published 1 October 2025 Volume 2025:20 Pages 11989—12007
DOI https://doi.org/10.2147/IJN.S542725
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Xing Zhang
Qianyue Zhang,1,* Shuanglan Xu,2,* Chunyan Yang,3,* Xiaolan Wang,1 Ting Liu,1 Xinting Zhang,2 Chongchang Qu,2 Jiawang Wu,1 Jiao Yang,4 Xiqian Xing2
1Kunming Medical University, Kunming, Yunnan, 650500, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Yunnan University, Key Laboratory of Respiratory Disease Research of Department of Education of Yunnan Province, Kunming, Yunnan, 650021, People’s Republic of China; 3Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (Kunming Hospital of Traditional Chinese Medicine), Kunming, Yunnan, 650500, People’s Republic of China; 4Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiqian Xing, Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Yunnan University, Key Laboratory of Respiratory Disease Research of Department of Education of Yunnan Province, Kunming, Yunnan, 650021, People’s Republic of China, Email xingxiqian@ynu.edu.cn Jiao Yang, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, People’s Republic of China, Email yangjiao@kmmu.edu.cn
Abstract: Chronic obstructive pulmonary disease (COPD), a leading global cause of mortality and morbidity, imposes substantial socioeconomic burdens due to its progressive nature and limited therapeutic efficacy. Current strategies face dual challenges: suboptimal pulmonary bioavailability of pharmacologic agents and systemic toxicity from non-targeted drug distribution. To address these limitations, this review establishes a mechanistic framework through the first systematic identification of COPD-specific nano-intervention targets, organized around four core pathophysiological axes: (1) dysregulated inflammatory cascades, (2) redox imbalance mechanisms, (3) protease-antiprotease homeostasis disruption, and (4) progressive airway remodeling. We critically evaluate respiratory-adaptive nanocarrier systems, including polymer nanoparticles (PLGA-PEG) with 6.5-fold enhanced Neutrophil targeting efficiency (*p* < 0.001) and lipid nanoparticles (LNPs) achieving > 90% siRNA-mediated inflammatory gene suppression. Despite advancements, clinical translation remains hindered by technical limitations in nanoparticle engineering, chronic pulmonary biocompatibility risks (eg, silica nanoparticles elevating TGF-β by 1.8-fold, *p* < 0.05), and stringent regulatory requirements. Future research must prioritize intelligent stimulus-responsive platforms for inflammation-triggered drug release, multidisease targeting nanotechnologies, and AI-driven patient-specific formulations. By integrating mechanistic insights with translational strategies, this work provides a roadmap to advance nano-interventions toward precision therapeutics for COPD.
Keywords: COPD, nanomaterial, drug delivery, targeted therapy, nanocarriers
1Kunming Medical University, Kunming, Yunnan, 650500, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Yunnan University, Key Laboratory of Respiratory Disease Research of Department of Education of Yunnan Province, Kunming, Yunnan, 650021, People’s Republic of China; 3Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (Kunming Hospital of Traditional Chinese Medicine), Kunming, Yunnan, 650500, People’s Republic of China; 4Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiqian Xing, Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Yunnan University, Key Laboratory of Respiratory Disease Research of Department of Education of Yunnan Province, Kunming, Yunnan, 650021, People’s Republic of China, Email xingxiqian@ynu.edu.cn Jiao Yang, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, People’s Republic of China, Email yangjiao@kmmu.edu.cn
Abstract: Chronic obstructive pulmonary disease (COPD), a leading global cause of mortality and morbidity, imposes substantial socioeconomic burdens due to its progressive nature and limited therapeutic efficacy. Current strategies face dual challenges: suboptimal pulmonary bioavailability of pharmacologic agents and systemic toxicity from non-targeted drug distribution. To address these limitations, this review establishes a mechanistic framework through the first systematic identification of COPD-specific nano-intervention targets, organized around four core pathophysiological axes: (1) dysregulated inflammatory cascades, (2) redox imbalance mechanisms, (3) protease-antiprotease homeostasis disruption, and (4) progressive airway remodeling. We critically evaluate respiratory-adaptive nanocarrier systems, including polymer nanoparticles (PLGA-PEG) with 6.5-fold enhanced Neutrophil targeting efficiency (*p* < 0.001) and lipid nanoparticles (LNPs) achieving > 90% siRNA-mediated inflammatory gene suppression. Despite advancements, clinical translation remains hindered by technical limitations in nanoparticle engineering, chronic pulmonary biocompatibility risks (eg, silica nanoparticles elevating TGF-β by 1.8-fold, *p* < 0.05), and stringent regulatory requirements. Future research must prioritize intelligent stimulus-responsive platforms for inflammation-triggered drug release, multidisease targeting nanotechnologies, and AI-driven patient-specific formulations. By integrating mechanistic insights with translational strategies, this work provides a roadmap to advance nano-interventions toward precision therapeutics for COPD.
Keywords: COPD, nanomaterial, drug delivery, targeted therapy, nanocarriers